BioStock: Biosergen on dosing the first patient with life-threatening fungal disease

The first patient has been dosed in Biosergen’s clinical phase Ib trial with BSG005, intended as rescue therapy for invasive fungal infection to increase survival rates for these critically ill patients. Topline results are anticipated by year-end or early 2025. BioStock reached out to CEO Tine Kold Olesen to learn more about the latest achievement.

Read the interview at biostock.se:

https://www.biostock.se/en/2024/07/biosergen-on-dosing-the-first-patient-with-life-threatening-fungal-disease/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/